Video
Dr. Gandara on the MYSTIC Trial for Lung Cancer
Author(s):
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC)
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC).
The results of the MYSTIC trial have been much anticipated, explains Gandara. This is a phase III trial in advanced-stage NSCLC, randomizing patients to standard-of-care platinum chemotherapy versus either durvalumab (Imfinzi) alone or durvalumab plus tremelimumab, a CTLA-4 inhibitor.
In a press release from AstraZeneca, it was reported that the primary endpoint of progression-free survival was not met in either of the experimental arms. No data have been reported in terms of the magnitude of benefit; it was just reported that the primary endpoint was not met, states Gandara.
